Shockwave therapy: the science
An in-depth overview of the mechanisms of action, clinical evidence, and honest limitations of low-intensity focused shockwave therapy for erectile dysfunction.
Seven mechanisms of action
Focused low-intensity shockwaves (LI-ESWT) do not work through a single mechanism. They are mechanical pressure waves that trigger a cascade of biological responses at the tissue level:
1. Neovascularisation (VEGF)
Shockwaves stimulate the production of Vascular Endothelial Growth Factor (VEGF), a growth factor that drives the formation of new small blood vessels. More capillaries in the erectile tissue means more blood flow and better engorgement.
2. Angiogenesis
In addition to new capillaries, the treatment also stimulates the outgrowth and strengthening of existing blood vessels. The vascular network becomes not only more extensive, but also more robust.
3. NO pathway (eNOS activation)
The shockwaves activate the enzyme endothelial nitric oxide synthase (eNOS). This enzyme produces nitric oxide (NO), the molecule that relaxes the smooth muscle cells in the vessel wall and thereby enables the erection. Greater eNOS activity means a stronger NO signal.
4. Stem cell recruitment
Mechanical pressure waves mobilise endogenous stem cells to the treated tissue. These stem cells contribute to the repair of damaged smooth muscle tissue and endothelium.
5. Fibrosis reduction
In chronic ED, fibrotic (scar) tissue forms in the corpora cavernosa, reducing elasticity. Shockwaves can partially reverse this process by stimulating collagen remodelling and improving the ratio of functional tissue to scar tissue.
6. Anti-inflammatory effect
Chronic low-grade inflammation plays a role in vascular decline. Shockwaves modulate the inflammatory process by stimulating the expression of anti-inflammatory cytokines and reducing pro-inflammatory markers.
7. Neurogenesis
There is cautious evidence that shockwaves can support the regeneration of cavernous nerves. This is particularly relevant after nerve-sparing prostatectomy, where the cavernous nerves are damaged or irritated.
Cochrane 2025: what the evidence says
The Cochrane Systematic Review (2025) is the most comprehensive meta-analysis to date. The key figures:
The conclusion: the average improvement is statistically significant. An improvement of 3 to 5.25 IIEF points can mean the difference for the individual patient between an erection that is lost halfway through and one sufficient for intercourse. The European Association of Urology (EAU) recognises LI-ESWT as a treatment option for vasculogenic ED based on this evidence.
Important: "average" conceals individual variation. In well-selected patients, we see the majority experience noticeable improvement. Some men little to none. That is precisely why patient selection and outcome tracking are essential, and why we do not treat without an intake consultation.
The IIEF scale explained
The International Index of Erectile Function (IIEF-EF) is the gold standard for measuring erectile function in clinical research. The scale runs from 1 to 25:
- 22 – 25 pointsNormal erectile function
- 17 – 21 pointsMild erectile dysfunction
- 12 – 16 pointsMild to moderate erectile dysfunction
- 8 – 11 pointsModerate erectile dysfunction
- 1 – 7 pointsSevere erectile dysfunction
An improvement of 4 points on the IIEF-EF scale is considered a category shift, for example from "mild to moderate" to "mild". That is the difference between an erection that is lost halfway through and one sufficient for intercourse.
Focused versus radial
There are two types of shockwave devices on the market. The difference is clinically relevant:
Focused shockwaves
Penetrate deeper into the tissue (up to 12 cm). The energy is concentrated on a precise focal point. This is the type studied in the majority of Cochrane trials and the type we use at REVIVO.
Radial pressure waves
Spread from the surface and rapidly decrease in intensity. Cheaper, more widely available, but with less penetration and less targeted energy delivery. The evidence for radial waves in ED is more limited.
Patient selection: who benefits most?
Not every man is an equally suitable candidate. The clinical evidence points to three profiles:
- Best candidatesMen with mild to moderate vasculogenic ED who still respond to PDE5 inhibitors. IIEF-EF score between 12 and 21. No severe fibrosis, no penile prosthesis, no uncontrolled diabetes.
- Good candidatesMen who no longer respond (sufficiently) to PDE5 inhibitors but still have functional erectile tissue. Rehabilitation after nerve-sparing prostatectomy. IIEF-EF score between 8 and 16.
- Limited candidatesMen with severe ED (IIEF-EF below 7), extensive fibrosis of the corpora cavernosa, severe uncontrolled diabetes, or purely psychogenic ED without a vascular component. In these cases, expectations are limited and we often recommend a different approach.
What you need to know
Transparency builds more trust than marketing claims. Here is the full picture:
- The evidence base is solid and growing: more than seven meta-analyses show significant improvement in erectile function. The EAU recognises LI-ESWT as a treatment option. At the same time, Cochrane classifies the evidence level as "low": that concerns the methodological quality of the studies, not the treatment itself.
- Results vary per patient: in well-selected patients, we see the majority experience improvement. Not equally strong in everyone. That is why we measure systematically and advise based on your own response.
- Long-term data are limited: most studies measure up to 6 or 12 months. Kitrey et al. (2018) showed sustained effect after 2 years, but broader long-term evidence is still lacking.
- Lifestyle matters: shockwave works best in combination with a healthy lifestyle. Sleep, nutrition, exercise, and stress reduction enhance the treatment effect.
- Not everyone is a candidate: for severe ED, extensive fibrosis, or purely psychogenic causes, we recommend a different approach. We discuss this during the intake consultation.